HCV Treatment
FDA Expands Harvoni Indication to Include Hepatitis C Genotypes 4-6 and HIV/HCV Coinfection
- Details
- Category: Approved HCV Drugs
- Published on Thursday, 19 November 2015 00:00
- Written by Gilead Sciences
The U.S. Food and Drug Administration last week granted supplemental approval of Gilead Sciences' sofosbuvir/ledipasvir (Harvoni) single-tablet regimen for the treatment of hepatitis C virus genotypes 4, 5, and 6 and for HIV/HCV coinfected people. The FDA also said Harvoni plus ribavirin for 12 weeks is an alternative to a 24 weeks of Harvoni alone for treatment-experienced hepatitis C patients with liver cirrhosis.
AASLD 2015: Sofosbuvir/ Ledipasvir + Vedroprevir Cures 96% of Cirrhotic Genotype 1 Patients
- Details
- Category: Experimental HCV Drugs
- Published on Wednesday, 18 November 2015 00:00
- Written by Liz Highleyman
A triple combination of Gilead Sciences' sofosbuvir/ledipasvir (Harvoni) plus the experimental HCV protease inhibitor vedroprevir cured 96% of treatment-experienced, cirrhotic, genotype 1 hepatitis C patients without the need for ribavirin, according to study findings presented at the AASLD Liver Meeting this week in San Francisco.
AASLD 2015: Sofosbuvir + Ravidasvir Shows High Response Rates for Genotype 4 Hepatitis C
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 17 November 2015 00:00
- Written by Liz Highleyman
A regimen of sofosbuvir and the pan-genotypic HCV NS5A inhibitor ravidasvir, with or without ribavirin, demonstrated sustained response rates ranging from 86% to 100% in the largest Phase 3 trial to date of interferon-free treatment for people with hepatitis C virus genotype 4, according to study findings presented at the 2015 AASLD Liver Meeting taking place this week in San Francisco.
AASLD 2015: New AbbVie Hepatitis C Combination Cures Up to 97% with Genotype 3
- Details
- Category: Experimental HCV Drugs
- Published on Wednesday, 18 November 2015 00:00
- Written by Keith Alcorn
A combination of 2 experimental direct-acting antivirals developed by AbbVie cured 83%-97% of people with genotype 3 hepatitis C after a 12-week course of treatment, Paul Kwo from Indiana University School of Medicine reported at the 2015 AASLD Liver Meeting this week in San Francisco.
AASLD 2015: New AbbVie Pangenotypic Regimen Cures 97%-100% of Hepatitis C Patients in Early Study
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 17 November 2015 00:00
- Written by Keith Alcorn
A combination of 2 experimental direct-acting antivirals developed by AbbVie cured 97% to 100% of non-cirrhotic people with genotype 1 hepatitis C in a mid-stage Phase 2 study presented this week at the AASLD Liver Meeting in San Francisco.
More Articles...
- AASLD 2015: Sofosbuvir/ Velpatasvir Shows High Cure Rates for All HCV Genotypes in Phase 3
- AASLD 2015: Sofosbuvir/ Velpatasvir + GS-9857 for 8 Weeks Cures Most Genotype 1 or 3 Hepatitis C Patients
- AASLD 2015: Grazoprevir/ Elbasvir Shows High Cure Rate for People Who Inject Drugs
- IDWeek 2015: HIV/HCV Coinfected People Achieve High Cure Rates with Grazoprevir/Elbasvir
Web Design and Development by